FountainVest to buy major stake in Italy's EuroGroup Laminations
The two investors said on Monday that EMS Euro Management Services had agreed to sell its 45.7% stake in EuroGroup Laminations to an investment vehicle owned by FountainVest for 3.85 euros per share, a 64% premium to Friday's closing price.
EMS would then reinvest 50% of the proceeds from the sale into a new holding company set up with FountainVest to own EuroGroup Laminations.
The investors said FountainVest had also struck a deal to buy Tikehau Capital's 7.9% stake in EuroGroup Laminations for the same price, meaning that at the closure of the deal - expected in the first half of 2026 - the new holding would own 55.3% of the voting share capital in EuroGroup Laminations.
It will then launch a tender offer for the rest of EuroGroup Laminations shares at 3.85 euros, valuing the company at 626 million euros ($730 million), with a view to delisting it from Euronext Milan.
At 1010 GMT, EuroGroup Laminations shares were up almost 54% at 3.58 euros.
FountainVest managing director and head of Europe Florian Almeling said the deal would support EuroGroup Laminations' global growth, "while delivering highly differentiated growth opportunities in Asia and other attractive global markets."
EuroGroup Laminations specialises in stators and rotors, two core components of electric motors and generators and has eight plants in Italy and seven abroad, including in China and the United States.
As part of the deal, EuroGroup Laminations CEO Marco Arduini and other top executives will be confirmed in their roles, the two investors said in a statement.
($1 = 0.8565 euros)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
12 minutes ago
- Reuters
India's Gland Pharma posts quarterly profit rise on Cenexi recovery, Europe sales growth
Aug 5 (Reuters) - India's Gland Pharma ( opens new tab reported a nearly 50% jump in first-quarter profit on Tuesday, driven by better margins and a recovery at its European unit Cenexi. The company reported a consolidated net profit of 2.15 billion rupees ($24.50 million) for the quarter ended June 30, from 1.44 billion rupees in the year-ago quarter. Revenue from operations rose 7.4% to 15.06 billion rupees. While sales from its U.S. business, which accounts for nearly half of the total, fell 2%, its Europe business posted a 29% rise. For further results highlights, click KEY CONTEXT Gland and several Indian pharma companies that make generic drugs derive a significant share of revenue from the United States and has continued to face pricing pressure in that market following U.S. President Donald Trump's imposition of hefty tariffs on goods imported from India. Rivals Sun Pharma ( opens new tab and Cipla ( opens new tab and Dr Reddy's ( opens new tab reported subdued U.S. sales in the quarter. However, Gland Pharma said improved margins and Cenexi's earnings before interest, taxes, depreciation, and amortisation (EBITDA) break-even supported quarterly performance, marking a turnaround after production setbacks at its Paris and Belgium units weighed on earnings over the past year. The company's EBITDA margin rose to 35% in the June quarter from 29% a year earlier. PEER COMPARISON * Mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell ** Ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT APRIL TO JUNE STOCK PERFORMANCE -- All data from LSEG -- $1 = 87.7570 Indian rupeesthe
BreakingNews.ie
13 minutes ago
- BreakingNews.ie
Salary overpayments to Revenue staff reached almost €1.7m in 2023
The value of salary overpayments to Revenue staff reached almost €1.7 million at the end of 2023, with more than 1 in 7 of its workforce getting paid above their proper salaries, according to the findings of an internal audit by the tax authorities. The audit report revealed that 61 Revenue employees had received overpayments above €5,000, while a further 424 staff members had been overpaid sums of between €1,000 and €5,000 during 2023. Advertisement Overpayments of €55,645 were identified as having been paid to 100 individuals who had not taken up employment as expected. Revenue auditors also described guidelines governing work processes, procedures and controls for the management of overpayments were 'dated and fragmented.' They concluded that only 'partial assurance' could be provided that Revenue's governance and procedures for monitoring and managing overpayments were robust and in line with civil service guidelines. The audit report, which was released under freedom of information legislation, found that no money had been repaid and/or no recoupment plan was in place for 212 out of 400 overpayment cases dating from 2002 to 2017. Advertisement The value of salary overpayments linked to these cases amounted to €296,642 In addition, money had only been recouped from 25 out of 188 remaining legacy cases that were classified as 'in progress.' The audit report shows that the salary overpayment balance in December 2023 was €1,679,140, representing approximately 0.45 per cent of the total wage bill for Revenue staff of €374.1 million that year. The total number of salary overpayment cases at the end of 2023 was 1,430. Advertisement They included 900 overpayments which had arisen during the course of the year to the value of €1.16 million – representing an average overpayment of just under €1,300. The report highlighted that no repayments had been made at the time in relation to 682 cases, while a further 28 cases had been deferred. Revenue reported that a total of 1,048 recoupment plans were in place during 2023, which resulted in repayments of €1.02 million and 767 cases being closed. The latest figures available show the outstanding balance for collection for overpayments at the end of June 2024 had increased to almost €1.8 million and involved a total of 1,611 cases. Advertisement At the time, 853 staff had not made any repayments to the tax authorities for overpayments to the value of €920,968. Revenue said the audit particularly focused on the effect that allowances, retirements, parental leave and promotions have on payroll. Auditors also examined payroll to identify potential risk indicators such as duplicate bank accounts, staff not taking any or the required minimum annual leave and cases that appeared to be on emergency tax for a prolonged period of time. The audit was carried out as an integrated audit with internal auditors from the National Shared Services Office (NSSO) – the Government's HR and payroll administration service. Advertisement Revenue's auditors said they had found 'evidence of a range of good work practices and internal controls in operation within Revenue regarding the management and monitoring of salary overpayments.' They noted that Revenue operates a dedicated overpayments unit with its staff actively managing cases on a day-to-day basis. However, the report accepted that there were 'opportunities for improvement.' The auditors also acknowledged that there was a lack of clarity on the responsibilities and requirements of Revenue and the NSSO in relation to some elements of managing cases of overpayments. An examination of a sample of 55 recent cases of overpayments found 58 per cent related to late applications by Revenue to the NSSO for parental leave or delayed notification by Revenue of events or changes that affected staff salary. Revenue auditors issued four recommendations as a result of the report, including one high-priority finding which called for a review of legacy overpayment cases 'with a view to actively progressing recoupment where possible.' Under a circular issued by the Department of Public Expenditure and Reform, monies owed by all civil servants, including retired employees, as a result of salary overpayments should be repaid to the Exchequer as soon as possible. Revenue said the most common causes of overpayments to its staff were allowances, parental leave, certified sick leave and resignations. All recommendations made in the report were accepted by Revenue management.
Times
13 minutes ago
- Times
Tesla UK sales drop 60 per cent in July
Tesla sales more than halved to below 1,000 in Britain last month as Chinese rivals continued to expand their foothold in the market. Its new car sales dropped 60 per cent in July to 987 units compared with 2,462 a year earlier as the electric carmaker struggles with regulatory challenges, fierce competition and a backlash against its chief executive Elon Musk's political views. The decline pushed its UK market share down to 0.7 per cent while China's BYD claimed 2.3 per cent of all new registrations, data from the Society of Motor Manufacturers and Traders (SMMT) showed. BYD sold 3,184 cars in Britain, up from 768 last year, while another Chinese brand, Jaecoo, also outsold Tesla with 1,915 new registrations, claiming 1.4 per cent of the market — up from zero sales last year when it launched in the UK.
